Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

Tu.B.2205, Tu.B.2209, Tu.C.2575,
We.A.3056, We.A.3067, We.A.3099,
We.A.3 02, We.A. 385, We. B. 3180,
We.B.3 81,We.B.3 194,
We.B.3 198
interleukins
Mo.A. 14 I Mo.A. 145, No.B.1319,
Pub.A. 1027, Pub.B. 105 I,Th.A. 164,
fh.A.390, Th.A.4052, Th.A.4059,
Th.B.4 I175, Th. B.4 I184, Tu.A.2030,
Tu.A.2 I100, Tu.A.272, We.A.3085,
We.A.3 1 00, We.B.290, We.B.292
interobserver variability
Th.C.2 14
interventions, community-based
Mo.C. 1609, MoC. 1630, Mo.D. 1697,
MoD.179 1, MoD. 1796, MoD. 1797,
Mo.D. 1799, Mo.D. 1800, MoD. 1801,
MoD. 1803, Mo.D. 1804, MoD. 1903,
Mo.D. 1906, MoD. 1916, MoD. 1944,
No.D. 1946, Mo.D.236, No.D.58 1,
No.D.60 1, Pub.B. 1039, Pub.C. 1 128,
Pub.C. 1253, Pub.C. 1272, Pub.D. 1295,
Pub.D. 1 308, Pub.D. 1 333, Pub.D. 1356,
Pub.D. 1367, Pub.D.1388, Pub.D.14 17,
Pub.D. 1433, Pub.D. 1434, Pub.D. 1455,
Rub..1461, Pub.D. I 469,Th.C.4425,
Th.C.4644, Th.C.4665, Th.C.4674,
Th.C.4759,Th.C.476 I,Th.C.4777,
Th.C.4786, Th.C.484 I, Th.C.4846,
Th.C.4857,Th.D.24 I,Th.D.254,Th.D.450,
Th.D.466,Th.D.500 I,Th.D.5072,
Th. D.5074, Th. D.5 191,Th. D.5 197,
Th.D.5200,Tu.C.2 I 5,Tu.C.2478,
Tu.C.2553,Tu.C.2649,Tu.C.2665,
Tu.C.267 I,Tu.C.453,Tu.D.27 19,
Tu.D.2776, Tu.D.2860, Tu.D.2877,
Tu.D.29 I 9,Tu.D.293 I,Tu.D.2933,
Tu.D.2934,Th.D.363, We.C.3487,
We.C.3526, We.C.3527, We.C.3563,
We.C.444, We.C.580, We.D.3622,
We.D.37 I19, We.D.3744, We.D.3766,
We.D.3773, We.D.3780, We D.3789,
We.D.38 I13, We.D.3845, We.D.3853,
We.D.3855, We.D.3861, We.D.387 I,
We.D.602
interventions, counselling
Ma.C. 1610, MoD. 1749, Mo.D. 1750,
MoD.1752, Mo.D,1756, MoD. 1758,
Mo.D. 904, Pub.C. 1 160, Pub.C. 1 165,
Pub.C. I1181, Pub.C. 1242, Pub.C. 1246,
Pub.D. I1297, Pub.D. I1383, Pub.D. I1483,
Th.C.4386,Th.C.4629,Th.C.4829,
Th.C.4830, Th.D.4906, Th.D.4982,
Th.D.5020, Th.D.5 I139, Th.D.5 148,
Th.D.5 I167, Tu.C.2457,Tu.C.452,
Tu.D.2729, Tu.[.2904, We.C.3492,
We.C.3564, We.D.375, We.D.3752,
We.D.3907
interventions, public awareness
campaigns
MoD. I134, MoD. 1762, MoD. 1766,
MoD.1819, Mo.D. 1820, MoD. 1832,
Mo.D. 1834, Mo.D. 1902, Mo.D. 1927,
Mo.D. 1928, Mo.D.25 1, Pub.C. 1 108,
Pub.C. 11I88, Pub.C. I1256, Pub.D. 1 302,
Pub.D. I1309, Pub.D. 1 360, Pub.D. 145 1,

We.C.445, We.D. I133, We.D.3853,
We.D,3855, We.D.6 14

intestine
No.8.1 14, No.. 11IS, No.8.1378,
Th.A.406 I, Th.B.4 I128, Y.B.4264,
Tu.A. I 42, Tu. B.2 199, We.A.3062,
We.B.3226, We.B.3 292, We,8.3293,
We.B.3299
intracellular immunisation
M o.A. 1034, M o.;. (II o.0. I045,
Mo.A. 1047
isolates, HIV
Mo.A.1003, Mo)/\. 9,N #A1074,
Mo.A.394, Mo.B.I I.7.Io'-.1463,
PubA10l I,PubA >)29, Pub.3. 1079,
Tu.A. 142,TuAA.26,Ti k2093. Tu.A.26 1,
We.A.3023, We. '9383 V/c.K.3 130,
We.B.335 I
isolates, replication
No.A. 1005, No.A I 064.o.A. 1074,
No.8.1335, Pub.A 10"9,TuA/.2049,
Tu.A.392
isolation
MoD. I135, PoL..03? Po.D. 1376,
Th.A.4050,Th.1{4 2 7;, 11.0.4632,
Tu.A.2042,TuB.?165,lo.D 2920,
We.A.30 IS
isolation from body fluds/sites
No.8. I1I5, Mo.B.1I364. iTu/A.2074,
We.B.33 I15
isoniazid
No.8. 1195, Mo.C 656, VWe.B.302,
We.B.3362
isospora belli
Pub.B. 1057, Pub.. 0u,8,11T,.8.47.68
itraconazole
No.8. I I I, No.8. 1 I16, PoLB. 1054,
Th.A.4062,Th.B.42 18,.10.6.2 1 96
justice
Th.D.4939
KAB (knowledge-attitudes-behaviour)
MoC. 1487, Mo.C. 1600, MoD[. 1696,
Mo.D. I1701, Mo..I1703, IN o. 1.706,
No.D. 1782, No.1), 1856, No.D. 1900,
Pub.C. I1I88, Pub.C. I1253, Pub.D. 1304,
Pub.D. 1305, Pub.D 1368, Pub.D. 1453,
Th.C.2 I12, Th.C.4440. TI C.41 72,
Th.C.4532,Th.C.44533,Th.C.-4594,
Th.C.4649,Th.D.453, 1h.D.493 I,
Th.D.5044,Th.D.5 I185, Io.C.25 I13,
Tu.C.2542, Tu.C.265 9,1 oh.C.2668,
Tu.D.2702,Tu.D,2768 TullE 279 1,
Tu.D.2962, We.C.350 7, We.D.3639,
We.D.3749, We.D.3880, We-.D.483
Kaplan-Meier analysis
Mo.C.32 I, Tu.B.3 I10, Tu. B.3 3.1T'U.C.435,
We.B.3 117, We.B.3380, We.C.3473
Kaposi's sarcoma
No.8.29,M..20M..21 M154, No.8. 1255, Mo.B.1295,
No.8.430, No.8.432, Mo.C. 1 560,
Mo.C. 1662, Pub.B.1061, Pub.B.1096,
Th.A.270, ThA.2 7,I 11A.72, Th.A.274,Th.A.4077 fhB4231 TuA.272,
Tu.B.2217,TuB22'8,o8.2219,
Tu.B.2223,TuB2224, 1i, 82225,
Tu.B.2228,TuB.3 I10.8.L2335,
We.A. 162, We.A. 13,WtA.166,
We.A. 167,We B 323/. 8..3238,
W.B-I-."-..3239.We 11 -1 e.B..31

No.8. 1248, No.8.1 283, No.8. 12.9 1,
No.8.434, Pub.B.1052, 1.A.)2/O,

Th.A.27 I, Th.A.272, Th.A.273, Th.A.274,
Th.A.2 75, Tu. B.22 I18, Tu.B8.2225,
We.A. I160, We.A. 161,We.A. I162,
We.A. 163, We.A, 164, We.A. 166,
We.A. 167, We.B.3233, We.B.3234,
We.B.3236
ketoconazole
No.8.1233
kidney
No.8.1263, No.8.1299, No.8. 1302,
Tu.A.2044,Tu.B.2232
kissing
Tu.A.2056
knowledge, SEE also survey
No.C. 1444, No.C. 1527, Mo.C.465,
NoD. 1704, NoD.,I1722, MNo.D. 1818,
Mo.D.1840, No.D.19 19, Pub.C.1231,
Pub.C. 1275, Pub.C. I1277, Pub.C. I1283,
Pub,D. I366, Pob.D. I 373,Th.C.4372,
T-h.C.4422, Th.C.4522, Th.C.4530,
Th.C.4565,T6.C 458 I,Th.C.4798,
TuC.2 I2.Tu.D.2742, We.C.3572
laboratory specimens
Tbh.B.4 I5 5, We.B.3 175
laboratory tests
No.A.5 13, No.8.1340, No.8.1364,
MoC. 1499,No.C. 1546, MoC. 1597,
Mo.C. 161 1, MoC. I635, MoC. I66!,
Pub.B. 1033, Pub.C. I I55,Th.A.40 I12,
Ih.A.4022,Th.A.403 I,Th.A.405 1,
Th. B.4 I15 I, Th. B.4 I155, Th. B.41I59,
Th.B.4 I 63,Th.B.4264,1-h.B.434 I,
Th.C.342, To A.2005,Tu.B.2 164,
Ti. B.2 I166, Tui.B.2 I174, Tu.B.2268,
Tu.B 2352, Wi\.3039, We.A.522,
We.B.3 I173, We.B.3 I175, We.D.3720
laboratory workers, SEE also occupational transmission
Th.C.47 13
Lamivudine (3TC)
Mo.A. I 103, No.A.380, No.8. 1120,
No.8. 1131, No.8. 1133, No.8. 1169,
No.8. 1328, No.8.133 1, No.8.1332,
No.8.1337, No.B.1354, No.8.290,
Th. B.295,TU.8B.2 I1I4, Tu. B.2 I126, Tu. B.2 I130,
fu.B.2 131,Tu.B.? I32,Tu.B.2308,
vWe.B.3 124, We.B.3 I135, We.B.3 137,
We.B.3 140
Langerhans cells
Tu.A.370
laser therapy
Tu.B.2.254. We.B.) I82
latency
MNo.A, 1004. MNo.A. 1024, Mo.A. 1064,
No.A. I 45, Th.C.?.05, Tu.A.2035,
We.A, 3087
law, legal aspects
NoD. 1950, No.D.364, Pub.C. 1249,
Pub.D. I1396, Pub. D. 1398, Pub.D. I1399,
Pub.D. 1400, Pub-D. 1407, Pub.D. 1472,
Th.D.4883,Th.D.4936,Th.D.4939,
2 h.D.4946, Th.D.4947,Th.D.4950,
Th.D.495 I, Th.D.4953,Th.D.4955.
Th. D.4995, Th.D.5030, Tu. D.28 I13,
Tu.D.2907, W.C.3559, We.C.3562,
We.C.3602, We.D.24 I, We.D.3644,
We.D.3646, We.D.3648, We.D.366 I,

We.D. 30. W.L.23 I, We.D.3644,
We.D.494

leishmaniasis
Th. B.421I7, Th. B.4220, Tu. B.22 3 I
length of stay (LOS)
Th.C.48 I4,Th.D.4880,Tu.B.2 I138,
Tu.B.2 I39, We.D.37 18
leprosy
No.8.1280
lesbians
Mo.D,.1710, Th. D.24 3, Th.D. 365,
Th.D.5 I 69,Tu.C.2455,Tu.C.2473,
Tu.C.2475, Tu.C.2476, Tu.C.2483,
Tu.D.2952,Tu.D.2957
leucovorin
Th.D.244
leukemia
No.8.1284, No.8. 1287, No.8.1292
life lost, years of potential (PYLL)
MoC.1542, No.C. 1544, No.C.444,
Th.D.4975, We.B.3339
ligase chain reaction (LCR)
Pub.A. 1005, No.A. 1057, Mo.A, 107 I,
Mo.A. 1095
lipids
Mo.A. I1101, No.8. 1382, No.8.1385,
Mo.8.424,Tu.A. I 44,Tu.B.2275, We.8. 185
liposomes
No.A, 1044, No.A. 1054, No.8.1256,
Th.A. I 5S,Tu.B.232 I
literature review
No.8.303, We.B.3240
liver
No.A. 1086, No.8.1238, No.8.1240,
N o.8B.1242, MNo.8B. 1275, Th.B8.4270,
l u.8.220 I, Tu.B.2204,Tu.B.2209,
We.B.3242
local immunity
Mo.A. 142, Pub.C. I1I85, Th.A.4055,
We.A.395
long terminal repeat (LTR)
No.A. 1023, No.A. 1035, No.A.500,
Mo.A.5O, No.A.502, Tu.A.2076
loviride (alpha APA)
Mo.A. I 065,Tu.B.23 18
lubricants, condom
Th.C.320
lung
No.8.1 14, No.8.1230, No.8.1373,
No.C. 1642, Pub.B. 1052, Pub.B. lOSS,
Pub.B. 1062, Pub.B. I 094,Th.A.4066,
Th.B.4230,Tu.B. I1I 0,Tu.B.2 I 96,Tu.B.222 I,
Tu.B.2358,Tu.B.2367, We.B.32 I1I,
We.B.322 I, We.B.3239, We.B.33 I15,
We.B.33 I17, We.B.3320, We.B.3322,
We.B.3358
lymph nodes
No.A. 1079, No.B.I1255, No.8. 1283,
No.8. 129 1, No.8.131 IN o.8.1335,
No.8.1373, No.B.4 14, Mo.C. 1507,
ThA. I102, Th.A. I155, Th.A. 161,Th.B.4329,
Tu.A.20 I16, Tu.A.2076, We.A. 3092,
We.A.385, We.A.402, We.B.3358
lymphocytes
No.A. 1013, Mo.A. 1046, No.A. 1057,
Mo.A. 1069, No.A. 1 104, Mo.A. I1109,
No.8.1345, No.8. 1350, Pub.B, 1072,
Th.A.40 I I,Th.A.4020,Th.A.4025,
Th.A.4052, Th.A.4054, Th. B. 172,

Th.B.423 I,'Th.B.4232,Th.B.4234,
Th.B.429 I,Tu.A. 1 54, Tu.B.2223, Tu.B.2253,

\0
0
0
U
C
0
U
C
0
Us
C
0)
C
490